Samsung Bioepis Moves Eylea Biosimilar To Phase III

Multiple Phase III Trials For Aflibercept Candidate In Progress

 
• By Dean Rudge
Eye
Samsung now has now pushed two ophthalmic biosimilars into Phase III trials • Source: Shutterstock

More from Biosimilars

More from Products